Collplant Holdings (CLGN) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CollPlant Biotechnologies has reported promising pre-clinical results for its innovative 3D-printed regenerative breast implants, designed to address a $3 billion market. Despite a decline in revenue, the company is actively pursuing collaborations to leverage its rhCollagen technology, aiming to enhance its financial position and advance its development programs.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
